文献速递妇科

阿贝西利联合来曲唑治疗子宫内膜样腺癌的手术窗口期临床试验

Surgical window of opportunity clinical trial of abemaciclib and letrozole for endometrioid adenocarcinoma of the endometrium.
PubMed 文献 · Gynecol Oncol · 2026-07-14

这项单臂前瞻性多中心手术窗口期试验纳入25例子宫内膜样腺癌患者,术前接受14天阿贝西利150mg每日两次联合来曲唑2.5mg每日一次。主要终点Ki-67从基线均值34%降至治疗后均值降低19%(SD 23%,p<0.001),达到预设终点,未记录严重不良事件。

要点

  • 阿贝西利联合来曲唑2周使子宫内膜样腺癌Ki-67平均降低19%(p<0.001)。
  • Ki-67降低幅度与pRb、PTEN、cyclin D1、p16或MMR蛋白状态无显著差异。
  • 短期治疗未记录严重不良事件。

核心结论

  • 阿贝西利联合来曲唑在术前两周内降低了子宫内膜样子宫内膜癌的细胞增殖。

研究设计与样本

  • 单臂前瞻性多中心手术窗口期临床试验,计划行子宫切除术的子宫内膜癌患者接受14天阿贝西利150mg每日两次和来曲唑2.5mg每日一次。
  • 中位年龄62岁(IQR 54-66),19名(76%)已绝经。

主要发现

  • 多数患者为白人(68%),24%为黑人;20%为西班牙裔。
  • 所有癌症均为子宫内膜样,多数FIGO 1级(76%),24%为2级。
  • 7名(28%)患者为错配修复缺陷肿瘤。
  • 基线Ki-67均值34%(SD 22%),治疗2周后平均降低19%(SD 23%,p<0.001),达到预设终点。
  • 根据pRb、PTEN、cyclin D1、p16或MMR蛋白,Ki-67降低幅度无显著差异。

关键数值与推荐

  • 主要终点为Ki-67(%)从治疗前活检到治疗后子宫切除标本的变化。
  • 预设终点为Ki-67显著降低,实际平均降低19%(SD 23%,p<0.001)。

临床怎么用

  • 短期术前阿贝西利联合来曲唑可降低子宫内膜样腺癌的增殖标志物Ki-67,且未记录严重不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Abemaciclib inhibits cyclin dependent kinases (CDK) 4 and 6 and, in synergy with anti-estrogens, is an FDA approved treatment of ER+ breast cancer. We hypothesized that letrozole and abemaciclib will inhibit cellular proliferation in patients with endometrial cancer. METHODS: This is a single-arm prospective multicenter surgical window of opportunity clinical trial for patients with endometrial cancer planned to undergo definitive management with hysterectomy. Patients received 14 days of abemaciclib 150 mg twice daily and letrozole 2.5 mg once daily. The primary endpoint was change in Ki-67 (%) from pretreatment biopsy to posttreatment hysterectomy specimen. Secondary endpoints included biological tumor characteristics (MMR, PTEN, PI3K, cyclin D1, pRB) associated with Ki-67 changes. RESULTS: Twenty seven women were enrolled, 2 patients withdrew consent leaving 25 evaluable patients. The median age was 62 (IQR: 54-66) and 19 patients (76%) were menopausal. Most patients were White (68%), 24% identified as Black; 20% were of Hispanic ethnicity. All cancers were endometrioid with the majority FIGO grade 1 (76%) and 24% grade 2. Seven (28%) patients had mismatch repair deficient tumors. Mean baseline Ki-67 was 34% (SD 22%). After 2 weeks of treatment, mean Ki-67 reduction was 19% (SD 23%, p < 0.001) meeting the prespecified endpoint. We found no significant difference in the magnitude of Ki-67 reduction based upon pRb, PTEN, cyclin D1, p16, or MMR proteins. There were no serious adverse events recorded. CONCLUSIONS: Abemaciclib and letrozole induced a reduction in cellular proliferation in endometrioid endometrial cancer over a short two-week time period prior to surgery.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Barber EL, Wei JJ, Strickland AL, et al. Surgical window of opportunity clinical trial of abemaciclib and letrozole for endometrioid adenocarcinoma of the endometrium. Gynecol Oncol. 2026. PMID: 42447658. doi:10.1016/j.ygyno.2026.07.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。